Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01966913 | Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors(TAXIFIII) | unknown | Phase 1 / Phase 2 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 |
| clinicaltrials |
| NCT03060850 | A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL | unknown | Phase 1 | 184 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03821363 | Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma | unknown | Phase 1 | 206 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT02032446 | Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease(PTC-UC-MSC) | unknown | Phase 1 / Phase 2 | 47 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT03796390 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia | unknown | Phase 1 | 15 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03312205 | CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02511301 | Circadian Thermal Sensing to Detect Breast Disease | unknown | Phase 1 / Phase 2 | 173 | Cyrcadia HealthINDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03672253 | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | unknown | Phase 1 | 20 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03674463 | LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | unknown | Phase 1 | 10 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | unknown | Phase 1 | 42 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03685786 | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | unknown | Phase 1 | 20 | Shenzhen Second People's HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02537977 | CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 60 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02719782 | A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation | unknown | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03731390 | GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03701451 | Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Wei JiangOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT03676946 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT03676985 | A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT02921685 | Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation(PIRAT) | unknown | Phase 1 | 18 | Institut Paoli-CalmettesOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT03639467 | Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03671460 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 | 18 | Tianjin Mycure Medical Technology Co., LtdINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03664661 | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Oncolys BioPharma IncINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT03631836 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma(MARELLE01) | unknown | Phase 1 | 34 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03599778 | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma | unknown | Phase 1 / Phase 2 | 52 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03528421 | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | unknown | Phase 1 | 30 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT03283943 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | unknown | Phase 1 | 22 | British Columbia Cancer AgencyOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03235973 | Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes(CEREAL) | unknown | Phase 1 | 29 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2019source: clinicaltrials